Found 513 results
Applegate’s experience underscores the challenge of identifying MS early while ensuring an accurate diagnosis.
STAT’s ESMO newsletter checks in from Madrid on Day 2, with one more edition due Monday and a live conference recap sche...
Intismeran cut recurrence or death risk by 42% alongside Keytruda, prompting melanoma specialists to consider adoption a...
Telehealth companies are marketing GLP-1 prescriptions for addiction as Lilly and other drugmakers test treatments for s...
A family called a frightening inherited illness “it” until learning its name gave their experience a new frame.
The ACA expanded coverage but failed to curb waste or rising costs, Dana Goldman argues, calling for stronger evidence o...
Workers paid an average $7,471 toward family plan premiums in 2026, a 9% increase as employers absorbed most rising heal...
STAT’s Health Tech newsletter previews the FDA’s final guidance on drug related apps and its implications for digital th...
Family coverage through employer health plans costs 9% more on average this year, with workers at small companies facing...
Quel, Livelyhood and Choose Your Horizon are offering off-label GLP-1 prescriptions for substance use, including compoun...
Lutikizumab improved hidradenitis symptoms in a Phase 3 trial, though the primary endpoint results left experts unsure i...
A large trial found Moderna and Merck’s personalized mRNA vaccine reduced melanoma recurrence risk by 42% versus standar...
After years of avoiding coverage of his ousting, David Sabatini describes the jury verdict in his civil case against Kri...
After years of losses and merger talks, the Michigan nonprofit reports a 70% profit margin following a government-backed...
The author’s parents, Fred and Regina Bosch, in 1989. They would both later kill themselves — Fred in 1995, Regina in 20...
Thrive Capital spent 18 months courting Isomorphic Labs, which aims to turn AlphaFold into a drug discovery engine. The...
In a Phase 2 study, Gilead’s oral emvistegrast achieved a 23% placebo-adjusted remission rate after 12 weeks in moderate...
Bart De Wever says U.S. and Chinese pressure threatens European pharma, citing GSK’s planned restructuring and competiti...
The No Surprises Act’s billing arbitration process has become highly profitable for some arbitrators, according to a STA...
Tyler Shultz argues that Nathan Fielder’s film creates ambiguity by omitting the Edison device, Theranos’ finances and H...